StreetInsider.com News Articles

Guggenheim Starts AN2 Therapeutics (ANTX) at Buy

Mon, 20 Jul 2026 02:52:35 -0400

Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ: ANTX) with a Buy rating and a price target of $9.00.

The analyst comments: “We think ANTX shares can experience significant upside within the next 18 months if epetraborole proves to be the first oral drug that controls hematocrit in patients with polycythemia vera (PV). Hematocrit control is the essential goal of therapy because it reduces thrombotic risk in patients with PV, but today it is poorly achieved with frequent phlebotomies (blood draws) and cytoreductive therapies that have toxicity. Epetraborole has a good tolerability profile, demonstrated over 6 months in another

Guggenheim Starts AN2 Therapeutics (ANTX) at Buy

Mon, 20 Jul 2026 02:52:35 -0400

Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ: ANTX) with a Buy rating and a price target of $9.00.

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Marks Gilbert Lynn

Fri, 10 Jul 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260710/26758273.html

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Marks Gilbert Lynn

Fri, 10 Jul 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260710/26758273.html

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Aziz Kabeer

Fri, 10 Jul 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260710/26758274.html

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Aziz Kabeer

Fri, 10 Jul 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260710/26758274.html

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Martin Patricia A.

Fri, 10 Jul 2026 19:40:00 -0400

si-local-file:///var/storage/secattach/20260710/26758272.html

Form 4 AN2 Therapeutics, Inc. For: Jul 10 Filed by: Martin Patricia A.

Fri, 10 Jul 2026 19:40:00 -0400

si-local-file:///var/storage/secattach/20260710/26758272.html

Form 4 AN2 Therapeutics, Inc. For: Jul 08 Filed by: Eizen Joshua M

Fri, 10 Jul 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260710/26758191.html

Form 4 AN2 Therapeutics, Inc. For: Jul 08 Filed by: Eizen Joshua M

Fri, 10 Jul 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260710/26758191.html

Form 8-K AN2 Therapeutics, Inc. For: Jun 03

Tue, 09 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260609/26619556.html

Form 8-K AN2 Therapeutics, Inc. For: Jun 03

Tue, 09 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260609/26619556.html

Form 8-K AN2 Therapeutics, Inc. For: Jun 04

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605930.html

Form 8-K AN2 Therapeutics, Inc. For: Jun 04

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605930.html

AN2 Therapeutics reports positive data for Chagas disease drug

Thu, 04 Jun 2026 07:01:02 -0400

AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.

In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.

A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.

The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998

AN2 Therapeutics reports positive data for Chagas disease drug

Thu, 04 Jun 2026 07:01:02 -0400

AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.

The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998

AN2 Therapeutics reports positive data for Chagas disease drug

Thu, 04 Jun 2026 07:01:02 -0400

AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.

The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998

AN2 Therapeutics reports positive data for Chagas disease drug

Thu, 04 Jun 2026 07:01:02 -0400

AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.

The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease